You just read:

Boston Biomedical Announces Presentations for Investigational First-in-Class Cancer Stemness Inhibitors Napabucasin and Amcasertib in Multiple Tumor Types at ASCO 2017

News provided by

Boston Biomedical, Inc.

18 May, 2017, 08:00 ET